Work

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection

Year: 2022

Type: article

Abstract: Talimogene laherparepvec (T-VEC) is a genetically modified, live herpes simplex virus type 1 (HSV-1) oncolytic therapy that was the United States Food and Drug Administration-approved in 2015 as monotherapy for unresectable melanoma.1 Although modifications to the HSV-1 genome result in attenuation of viral pathogenicity, localized herpetic infections following T-VEC administration have been reported both in initial clinical trials and rare cases.2,3 Although T-VEC–induced disseminated herpes infection, particularly in the setting of immunosuppression, is a theoretical adverse effect, disseminated herpes infection because of T-VEC administration has been suggested only in 1 case report.

Source: JAAD Case Reports

DOI: 10.1016/j.jdcr.2022.09.012

Authors: Leonid Shmuylovich, Aubriana M. McEvoy, Ryan C. Fields, Leonel Hernandez-Aya, George Ansstas, David Y. Chen

Institutions: Washington University in St. Louis, University of Miami

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $675